文献速递胸部肿瘤放疗放疗物理与技术

肺癌功能性肺避让放疗的前瞻性试验:生活质量报告

Prospective Trial of Functional Lung Avoidance Radiation Therapy for Lung Cancer: Quality of Life Report.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-04-12

一项2期多中心4DCT-通气功能性避让临床试验纳入接受根治性放疗的局部晚期肺癌患者,用FACT-L问卷在治疗前、治疗结束时及治疗后3、6、12个月评估患者报告结局,分析临床有意义下降的比例及预测指标。结果显示12个月时约30%患者出现临床有意义下降,多数剂量与剂量-功能参数增加与PRO轻度下降相关但均无统计学显著性(所有P > .053)。

要点

  • 12个月时FACT-试验结局指数临床有意义下降比例为26.8%,FACT-肺癌亚量表为29.3%。
  • 多数剂量与剂量-功能参数增加与PRO轻度下降相关,但均无统计学显著性(所有P > .053)。
  • 该研究首次报告前瞻性4DCT-通气功能性避让治疗患者的患者报告结局。

核心结论

  • 该研究首次报告前瞻性4DCT-通气功能性避让治疗患者的患者报告结局,约30%患者在治疗后12个月出现患者报告结局的临床显著下降。

研究设计与样本

  • 2期多中心4DCT-通气功能性避让临床试验,纳入接受根治性放疗的局部晚期肺癌患者,共59例完成基线PRO问卷。

主要发现

  • 59例完成基线PRO问卷的患者中83%为非小细胞肺癌,75%为3期疾病,中位剂量为60 Gy分30次。
  • FACT-试验结局指数临床有意义下降在3、6、12个月分别为46.3%、38.5%、26.8%。
  • FACT-肺癌亚量表临床有意义下降在3、6、12个月分别为33.3%、33.3%、29.3%。
  • 多数剂量与剂量-功能参数增加与PRO轻度下降相关,但均无统计学显著性(所有P > .053)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A novel form of lung function imaging has been developed that uses 4-dimensional computed tomography (4DCT) data to generate lung ventilation images (4DCT-ventilation). Functional avoidance uses 4DCT-ventilation to reduce doses to functional lung with the aim of reducing pulmonary side effects. A phase 2, multicenter 4DCT-ventilation functional avoidance clinical trial was completed. The purpose of this work was to quantify changes in patient-reported outcomes (PROs) for patients treated with functional avoidance and determine which metrics are predictive of PRO changes. MATERIALS AND METHODS: Patients with locally advanced lung cancer receiving curative-intent radiation therapy were accrued. Each patient had a 4DCT-ventilation image generated using 4DCT data and image processing. PRO instruments included the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire administered pretreatment; at the end of treatment; and at 3, 6, and 12 months posttreatment. Using the FACT-Trial Outcome Index and the FACT-Lung Cancer Subscale results, the percentage of clinically meaningful declines (CMDs) were determined. A linear mixed-effects model was used to determine which patient, clinical, dose, and dose-function metrics were predictive of PRO decline. RESULTS: Of the 59 patients who completed baseline PRO surveys. 83% had non-small cell lung cancer, with 75% having stage 3 disease. The median dose was 60 Gy in 30 fractions. CMD FACT-Trial Outcome Index decline was 46.3%, 38.5%, and 26.8%, at 3, 6, and 12 months, respectively. CMD FACT-Lung Cancer Subscale decline was 33.3%, 33.3%, and 29.3%, at 3, 6, and 12 months, respectively. Although an increase in most dose and dose-function parameters was associated with a modest decline in PROs, none of the results were significant (all P > .053). CONCLUSIONS: The current work presents an innovative combination of use of functional avoidance and PRO assessment and is the first report of PROs for patients treated with prospective 4DCT-ventilation functional avoidance. Approximately 30% of patients had clinically significant decline in PROs at 12 months posttreatment. The study provides additional data on outcomes with 4DCT-ventilation functional avoidance.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lombardo J, Castillo E, Castillo R, et al. Prospective Trial of Functional Lung Avoidance Radiation Therapy for Lung Cancer: Quality of Life Report. Int J Radiat Oncol Biol Phys. 2024. PMID: 38614278. doi:10.1016/j.ijrobp.2024.03.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。